These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7849357)

  • 1. Lack of nephrotoxicity with the administration of amphotericin B in a lipid emulsion.
    Smith TM; Strozyk WR
    Ann Pharmacother; 1994 Nov; 28(11):1307-8. PubMed ID: 7849357
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralipid in prophylaxis of amphotericin B nephrotoxicity.
    Vita E; Schroeder DJ
    Ann Pharmacother; 1994 Oct; 28(10):1182-3. PubMed ID: 7841575
    [No Abstract]   [Full Text] [Related]  

  • 3. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation.
    Branch RA
    Arch Intern Med; 1988 Nov; 148(11):2389-94. PubMed ID: 3056312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity in the setting of invasive fungal diseases.
    Ullmann AJ
    Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline.
    Branch RA; Jackson EK; Jacqz E; Stein R; Ray WA; Ohnhaus EE; Meusers P; Heidemann H
    Klin Wochenschr; 1987 Jun; 65(11):500-6. PubMed ID: 3475498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.
    Mistro S; Maciel Ide M; de Menezes RG; Maia ZP; Schooley RT; Badaró R
    Clin Infect Dis; 2012 Jun; 54(12):1774-7. PubMed ID: 22491505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administering amphotericin B--a practical approach.
    Khoo SH; Bond J; Denning DW
    J Antimicrob Chemother; 1994 Feb; 33(2):203-13. PubMed ID: 8182001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function.
    Burgess JL; Birchall R
    Am J Med; 1972 Jul; 53(1):77-84. PubMed ID: 4667504
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity.
    Razzaque MS; Hossain MA; Ahsan N; Taguchi T
    Nephron; 2001 Nov; 89(3):251-4. PubMed ID: 11598385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients.
    Hall P; Kennedy G; Morton J; Hill GR; Durrant S
    Intern Med J; 2005 Jun; 35(6):374. PubMed ID: 15892774
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function.
    Burges JL; Birchall R
    Am J Med; 1972 Jul; 53(1):77-84. PubMed ID: 5037291
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
    Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
    Bes DF; Rosanova MT; Sberna N; Arrizurieta E
    Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of the use of liposomal amphotericin B].
    González Martínez M; Mariño Martínez C; Baldominos Utrilla G; Fernández Martínez MN
    Rev Iberoam Micol; 2014; 31(2):109-13. PubMed ID: 23711815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: Amphotericin pharmacophobia and renal toxicity.
    Forgan-Smith R; Darrell JH
    Br Med J; 1974 Feb; 1(5901):244. PubMed ID: 4818170
    [No Abstract]   [Full Text] [Related]  

  • 20. Amphotericin B--specifics of administration.
    Goodman JS; Koenig MG
    Mod Treat; 1970 May; 7(3):581-95. PubMed ID: 4920806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.